[Application of Neoadjuvant Chemoimmunotherapy in Resectable NSCLC]

Area of Science:

• Oncology
• Immunotherapy
• Surgical Oncology

Context:

• Resectable non-small cell lung cancer (NSCLC) presents treatment challenges.
• Neoadjuvant chemoimmunotherapy has shown promise in clinical trials.
• Real-world validation of neoadjuvant chemoimmunotherapy is crucial for widespread adoption.

Purpose:

• To evaluate the safety and feasibility of neoadjuvant chemoimmunotherapy in a real-world setting for NSCLC.
• To compare event-free survival (EFS) and major pathologic response (MPR) between neoadjuvant chemoimmunotherapy and chemotherapy alone.
• To assess overall survival (OS), treatment-related adverse events (TRAEs), and surgical outcomes.

Summary:

• Neoadjuvant chemoimmunotherapy demonstrated superior MPR (57.4% vs. 14.3%) and pCR (46.3% vs. 0%) compared to chemotherapy alone.
• At 24 months, EFS rates were 77.0% for chemoimmunotherapy versus 56.7% for chemotherapy alone (P=0.026).
• Overall survival rates at 24 months were 87.1% for chemoimmunotherapy versus 67.7% for chemotherapy alone (P=0.020).

Impact:

• Neoadjuvant chemoimmunotherapy is an effective treatment for resectable NSCLC, improving patient survival and response rates.
• This approach does not appear to increase surgical complications or operative difficulty.
• Real-world data support the use of neoadjuvant chemoimmunotherapy, reinforcing its clinical utility.